The Covid pandemic accelerated the development of cancer vaccine

The Covid pandemic gave a major boost to the vaccine field. The Danish biotech company Expres2ion Biotechnologies, which is developing a vaccine against breast ...

Founder of Bioarctic, Lars Lannfelt, is honoured: “I want to create something for the future”

It´s like a scientist’s dream: to be the world’s first with a drug that genuinely affects one of our major diseases. Lars Lannfelt and his company Bioarctic hav...

FHM ska leda expertlabb för ebola och okända virussjukdomar

Folkhälsomyndigheten har fått ansvar för att driva det europeiska referenslaboratoriet för smittsamma sjukdomar som ebola, marburg och rabies. Uppdraget omfatta...

Högt deltagande på konferens om biologiska läkemedel

Drug development booms in Medicon Valley

When it comes to developing new medicines, the Öresund region is one of the top performers in the EU. Companies working on commission for pharmaceutical compani...

Roche’s Genentech terminates licencing deal with Norwegian biotech

Genentech is ending a license collaboration with Norwegian biotech Nykode Therapeutics regarding a clinical stage cancer vaccine program.

Konsultbolag slås ihop – Scandinavian CRO och Qadvis blir Aurevia

Scandinavian CRO och Qadvis har nu bägge officiellt blivit en del av Aurevia, och tar därmed det nya bolagets namn.

Samuel Lagercrantz: The government’s performance in healthcare and life sciences so far

Since the change of government in Sweden, developments in the healthcare sector have shown promising signs, but the outlook in life sciences is less promising, ...

Software Point AB

Precision medicine centre: “Extensive activity on several fronts”

Two years ago, the Karolinska Institutet and the Karolinska University Hospital announced that they would jointly launch the Precision Medicine Centre. Medtech ...

AZ gets approval for drug targeting rare disease – it may reduce cortisone dependence

AstraZeneca’s drug Fasenra gets an expanded indication in the EU and is now approved as a treatment for the rare autoimmune disease known as Churg-Strauss syndrome.

KI-studie: Nässköljning kunde ge information om KOL

Förekomsten av ett visst protein i näsan kunde användas som underlag för bedömning av KOL, i en ny studie från forskare vid Karolinska institutet.

Cavidi AB

New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Stockholm (2026)

Pfizer’s Paxlovid is being tested against post-COVID in a major Swedish study

In a new study conducted at the Karolinska University Hospital, Pfizer’s COVID drug, Paxlovid, is now being tested in patients with post-COVID. The study is one...

No longer afraid of the dentist.

Teaching robot with piezo technology

The life science strategy – what the industry wants

The process of updating the national life science strategy has begun at the government’s life science office. According to industry stakeholders, Sweden’s compe...

Niklas Arnberg om årets framsteg: ”Obeskrivligt värdefullt”

Nu nalkas vinterns ledigheter. Det vill Life Science Sweden uppmärksamma genom att ställa bakåt- och framåtblickande frågor till bransch- och forskarprofiler fr...

The International Vaccine Institute’s office in Sweden is expanding

The International Vaccine Institute’s Stockholm office has been open for over a year. During the past year, training programmes and projects have been launched,...

Just four weeks to a concept for an emergency ventilator

The lockdown in spring 2020 meant that the majority of Festo employees had to join the ranks of those working from home. Yet within the space of just four weeks...

Festo AB

Astra Zeneca gör ny jätteinvestering i USA

Astra Zeneca satsar på nytt i USA. För motsvarande drygt 19 miljarder kronor fördubblar läkemedelsjätten sin produktionskapacitet för biologiska läkemedel i Maryland.

Decades of research destroyed at KI – a hacker attack cannot be ruled out!

Years of research, together with half a billion Swedish krona, went up in smoke when the freezers at Karolinska Institutet overheated. The breakdown has now bee...

Novo Nordisk establishes new factory in Denmark

Novo Nordisk establishes a new production facility in Odense, Denmark, an investment of 8.5 billion Danish kroner.